Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy.
Flu pandemics (worldwide epidemics) have occurred at irregular and unpredictable intervals, and have been associated with substantial morbidity, mortality and economic cost. In response to the emerging potential for a new pandemic to occur, national and international preparedness plans are being drawn up specifying the use of antivirals and vaccines. A number of challenges to pandemic vaccine development, large-scale production and the timing of distribution have also been highlighted. This article reviews the rationale and consequential policy for aligned public- and private sector planning in the present inter-pandemic period despite the prevalent risks and uncertainties. We propose a model for product development of pandemic flu vaccine based on public-private partnership, including push and pull incentive mechanisms for stimulating work in this therapeutic area. In addition, we argue that innovative vaccination strategies, together with special vaccine formulations which may offer cross-protection against multiple flu pandemic strains might avert the worse effects of an influenza infection.
Daems
Rudi
R
Chiron Vaccines, Policy and Corporate Affairs, Oxford, UK. rudi_daems@chiron.com
Del Giudice
Giuseppe
G
Rappuoli
Rino
R
D004196:Disease Outbreaks / Q000517:prevention & control*; D014943:Global Health; D006284:Health Plan Implementation; D006285:Health Planning; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D008954:Models, Biological; D009975:Orthomyxoviridae / Q000235:genetics / Q000276:immunology; D011634:Public Health; D014611:Vaccination
D007252:Influenza Vaccines